-+ 0.00%
-+ 0.00%
-+ 0.00%

Imunon sets R&D Day to spotlight IMNN-001 clinical progress

PUBT·09/09/2026 12:32:05
Listen to the news
Imunon sets R&D Day to spotlight IMNN-001 clinical progress
  • Imunon will host an R&D Day in New York City on Sept. 23, 2026, starting 10:00 a.m. ET.
  • Event will highlight clinical progress for IMNN-001, its investigational IL-12 immunotherapy in advanced ovarian cancer.
  • Agenda includes updates on the Phase 3 OVATION 3 trial, Phase 2 MRD study, translational data, management strategy discussion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Imunon Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609090830PRIMZONEFULLFEED9823618) on September 09, 2026, and is solely responsible for the information contained therein.